Status:
UNKNOWN
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer
Lead Sponsor:
AHS Cancer Control Alberta
Conditions:
Colon Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Cancer of the colon and rectum are the third most common cancers in Canadian males and females. The initial therapy of colorectal cancer is surgery to remove the cancer and nearby lymph glands. If the...
Detailed Description
Hypothesis: Recently, the thymidylate synthase gene's promoter has been found to be polymorphic, with variable numbers of tandem repeats of 28 base pairs in length. These polymorphisms have been asso...
Eligibility Criteria
Inclusion
- To be treated with 5FU/LV
Exclusion
- Abnormal liver or kidney function
Key Trial Info
Start Date :
August 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2017
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00131599
Start Date
August 1 2002
End Date
July 1 2017
Last Update
January 16 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2